NUTEX HEALTH PROVIDES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS, ANNOUNCES DELAY IN FILING ITS 2025 SECOND QUARTER FINANCIAL STATEMENTS AND ANNOUNCES A STOCK REPURCHASE PROGRAM OF UP TO $25 MILLION
1. Nutex Health delays filing Form 10-Q due to non-cash adjustments. 2. Preliminary Q2 2025 revenue rose 220.7% from Q2 2024. 3. Stock repurchase program of $25 million aims to bolster shareholder value. 4. Gross profit for Q2 2025 was $124.9 million, marking a significant increase. 5. Total assets reached $855.1 million with substantial cash reserves.